184 related articles for article (PubMed ID: 12071942)
1. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.
Mori A; Tamaru J; Sumi H; Kondo H
Eur J Haematol; 2002 Apr; 68(4):243-6. PubMed ID: 12071942
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma.
Bauduer F
Br J Haematol; 2001 Mar; 112(4):1085-6. PubMed ID: 11324638
[No Abstract] [Full Text] [Related]
3. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.
Tanaka H; Hashimoto S; Sugita Y; Sakai S; Takeda Y; Abe D; Takagi T; Nakaseko C
Int J Hematol; 2012 Oct; 96(4):501-5. PubMed ID: 22878940
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
6. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
Jourdan E; Topart D; Richard B; Jourdan J; Sotto A
Leuk Lymphoma; 2003 May; 44(5):889-90. PubMed ID: 12802933
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature.
Nader K; Patel M; Ferber A
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):511-3. PubMed ID: 23726016
[No Abstract] [Full Text] [Related]
8. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
10. Treatment of childhood autoimmune haemolytic anaemia with rituximab.
Quartier P; Brethon B; Philippet P; Landman-Parker J; Le Deist F; Fischer A
Lancet; 2001 Nov; 358(9292):1511-3. PubMed ID: 11705566
[TBL] [Abstract][Full Text] [Related]
11. [Alleviated anemia by bendamustine in cold agglutinin disease associated with small lymphocytic lymphoma].
Kuno M; Inoue A; Aimoto M; Nakao T; Kameda K; Yoshida M; Kanashima H; Hirai M; Yamane T
Rinsho Ketsueki; 2015 Feb; 56(2):204-9. PubMed ID: 25765801
[TBL] [Abstract][Full Text] [Related]
12. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma.
Cohen Y; Polliack A; Zelig O; Goldfarb A
Leuk Lymphoma; 2001; 42(6):1405-8. PubMed ID: 11911426
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Seipelt G; Böhme A; Koschmieder S; Hoelzer D
Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease.
Vassou A; Alymara V; Chaidos A; Bourantas KL
Int J Hematol; 2005 Jun; 81(5):421-3. PubMed ID: 16158824
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
Swords R; Nolan A; Fay M; Quinn J; O'Donnell R; Murphy PT
Clin Lab Haematol; 2006 Feb; 28(1):57-9. PubMed ID: 16430461
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus.
Kotani T; Takeuchi T; Kawasaki Y; Hirano S; Tabushi Y; Kagitani M; Makino S; Hanafusa T
Lupus; 2006; 15(10):683-5. PubMed ID: 17120596
[TBL] [Abstract][Full Text] [Related]
18. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
19. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma.
Hofer S; Hunziker S; Dirnhofer S; Ludwig C
Br J Haematol; 2003 Aug; 122(4):690-1. PubMed ID: 12899729
[No Abstract] [Full Text] [Related]
20. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.
Gupta N; Kavuru S; Patel D; Janson D; Driscoll N; Ahmed S; Rai KR
Leukemia; 2002 Oct; 16(10):2092-5. PubMed ID: 12357362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]